Phase 2b Trial Results: Patients using Enobosarm alongside metabolic therapy reduced lean mass loss to just 9.4%, with the Enobosarm 3mg group nearly eliminating lean mass loss altogether at just 0.9%.
Fat Reduction: An estimated 90.6% of total reduction came from fat, and for the Enobosarm 3mg group, that number soared to 99.1%—virtually pure fat loss.
Physical Function Improvements: Patients using Enobosarm alongside metabolic therapy saw a 62.4% reduction in significant (>10%) stair climb power loss.
Market Opp. and Future Outlook:
Veru Inc. is moving toward a pivotal Phase 3 trial. With millions of people using current metabolic therapies and no FDA-approved solution to protect muscle mass, Veru Inc. (Nasdaq: VERU) could be at the center of one of the most critical innovations in body composition and metabolic health.
Management Team:
Veru Inc. is led by an experienced management team with expertise in drug development, regulatory affairs, and corporate strategy.
Dr. Mitchell Steiner (CEO): Decades of experience in urology, oncology, and pharmaceutical leadership.
Dr. Etan Fisch (Co-founder): Expertise in urology and reproductive medicine.
Dr. Gary Barnette (Chief Regulatory Officer): Extensive regulatory and clinical development experience, including time at the FDA.
-----
Recap: 6 Potential Catalysts To Consider For (Nasdaq: VERU)
(1). The Metabolic Health Market Is Projected To Expand From $46Bn In 2024 To Over $470Bn Within A Decade, Representing +900% Growth.
(2.) Current Treatments Often Cause Lean Muscle Loss, But Veru Inc. Is Developing A Solution To Address This Critical Gap.
(3.) Enobosarm Is A Selective Androgen Receptor Modulator Designed To Reduce Fat While Preserving Muscle Mass.
(4.) Phase 2b Clinical Trials Showed Enobosarm Significantly Reduced Lean Muscle Loss Compared To Conventional Treatments, With Extension Results Expected In Q2 2025.
(5.) Wall Street Firms And Bill-ion-aire In-vest-or Have Expressed Confidence In Veru Inc.'s Upside Potential.
(6.) If Approved, Enobosarm Could Transform The Metabolic Health Market By Setting A New Standard For Muscle Preservation And Fat Reduction.
-----
Veru Inc. (Nasdaq: VERU) presents a compelling watchlist opp. within the rapidly growing metabolic health market.
Its novel approach to preserving muscle mass during wei-ght loss, combined with promising clinical results and growing industry attention, positions the company for strong success potential.
Coverage is officially initiated on Veru Inc. (Nasdaq: VERU). I'll be in touch with updates soon.
Sincerely,
Kai Parker
StockWireNews
No comments:
Post a Comment